Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Heron Therapeutics Inc (HRTX), La Jolla Pharmaceutical Company (LJPC), Salix Pharmaceuticals, Ltd. (SLXP) Are Tang Capital’s Largest Bets in Q4

Kevin Tang‘s Tang Capital Partners is one of the funds that have already revealed their equity portfolios as of the end of last year. The healthcare-focused investment firm reported an equity portfolio valued at $182.38 million, down from $193.00 million in the previous quarter. In this article we are going to take a closer look at Tang’s track record and will discuss in detail its top three largest holdings in terms of value, which are represented by Heron Therapeutics Inc (NASDAQ:HRTX)La Jolla Pharmaceutical Company (NASDAQ:LJPC), and Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP). These three stakes amass around 68% of the fund’s equity portfolio value.

Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP)

Tang Capital Partners was founded by Kevin Tang in 2002. Mr. Tang has an extensive experience of 19 years in evaluating biopharmaceutical companies from the perspective of portfolio manager and also as a financial analyst at Deutsche Bank Alex. Brown. Moreover, Mr. Tang serves on the board of several companies, including Heron Therapeutics Inc (NASDAQ:HRTX), and La Jolla Pharmaceutical Company (NASDAQ:LJPC). Mr. Tang’s fund has an impressive track record and since its inception managed to provide sold returns to its investors. Since its inception in 2002 aand until June 2010, Tang provided total returns net of all fees and expenses of 520%, while its annualized rate of return amounted to 26%.

Let’s talk about Tang’s largest equity stakes as of the end of 2014. On the first place is Heron Therapeutics Inc (NASDAQ:HRTX), where Mr. Tang serves as a board director. In its latest 13F filing, Tang Capital reported ownership of around 4.92 million shares of the company, valued at $49.49 million. The fund first disclosed shares of Heron Therapeutics Inc (NASDAQ:HRTX) in its 13F for the first quarter of 2014, initially holding around 4.41 million shares. Overall, the stock of the $249 biopharmaceutical company gained around 13% during the last year. Also, at the beginning of 2014, Heron Therapeutics changed its name from A.P. Pharma and conducted a 1-for-20 reverse stock split aimed to increase its share price. Moreover, its last financial report showed a significant year-on-year increase in revenues to $15 million, from $6.0 million a year ago and the company also narrowed its net loss to $0.66 from $0.80.

Another shareholder of Heron Therapeutics Inc (NASDAQ:HRTX) is Kevin Kotler‘s Broadfin Capital, which reported ownership of 2.81 million shares, held as of the end of June. Venrock Healthcare Capital Partners, an investor that focuses entirely on biotech stocks, also disclosed ownership of around 1.1 million shares.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.